HopeStage
Back to all studies
CompletedNCT00826202

D-serine as early support for schizophrenia symptoms

About this titleRead the official source — NCT00826202
Medication studyAges 13–35United States
The study in practice

Understand this study

Who was this study for?

Listed age limits: 13 years to 35 years.

Listed locations
New Haven and 3 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateMarch 2009
Recruitment status
Completed
Enrollment listed in the registry
44
Sponsor
Nathan Kline Institute for Psychiatric Research
Sponsor type
Research institute
Study type
Drug
Intervention type
Drug, Other
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 13 Years to 35 Years
Official registry ID
NCT00826202
Official title
Show the full official title

D-Serine vs Placebo for the Schizophrenia Prodrome

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

New Haven · Glen Oaks · New York

1 more locations
  • Orangeburg

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Nathan Kline Institute for Psychiatric Research, a research institute.

Did this study involve medication?

Yes. The study involved medication, including D-serine.

Who was this study for?

Listed age limits: 13 years to 35 years.

Want to explore more studies?

Explore studies